[1] Konstam M A, Kramer D G, Patel A R, et al. l eft ventricular remodeling in heart failure: current concepts in clinical significance and assessment[J]. JACC Cardiovasc Imaging, 2011, 4(1):98-108 [2] Scarpello J H, Howlett H C. Metformin therapy and clinical uses[J]. Diab Vasc Dis Res, 2008, 5(3): 157-167. [3] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Eur Heart J, 2013, 34(28): 2159-2219. [4] Zhang P, Hu X, Xu X,et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice[J].Hypertension, 2008 , 52(5):918-924. [5] Fu Y N, Xiao H, Ma X W, et al. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation[J]. Acta Pharmacol Sin, 2011,32(7): 879-887. [6] 张成喜, 潘思年 ,蒙荣森 ,等. 二甲双胍对压力超负荷大鼠心肌肥厚的影响[J]. 中国病理生理杂志 , 2010,26(2):238-244 . [7] 张成喜, 蒙荣森, 熊肇军, 等. 二甲双胍对原发性高血压患者左心室肥厚的影响 [J]. 中山大学学报 : 医学科学版 , 2009, 30(4s): 137-141. [8] Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials[J]. Diabetes Obes Metab, 2011, 13(3): 221-228. |